Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Total parenteral nutrition (TPN) in patients who cannot tolerate adequate oral or enteral nutrition,Peripheral parenteral nutrition (PPN) when central venous access is not available
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Not applicable as TRAVASOL 4.25% IN DEXTROSE 25% is a nutrient solution, not a drug with a defined elimination half-life.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids undergo deamination and transamination in the liver; dextrose is metabolized via glycolysis and the citric acid cycle; insulin secretion increases in response to dextrose.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
The amino acids and dextrose are completely metabolized; no significant renal or biliary excretion of intact product.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Not applicable; amino acids and dextrose do not bind to plasma proteins.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Not applicable; distributes throughout total body water.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100% bioavailable.
Intravenous: 100%.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 50% or monitor BUN and creatinine; GFR <10 m L/min: avoid unless on dialysis; adjust based on nitrogen balance and fluid status.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor ammonia; Child-Pugh C: avoid use due to risk of encephalopathy from amino acid load.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Neonates and infants: initial 0.5-1 g amino acids/kg/day, increase gradually to 2-3 g/kg/day; dextrose initial 4-6 mg/kg/min, titrate up to 12-15 mg/kg/min; continuous infusion via central vein.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Start at lower end of dose range (0.5-1 g amino acids/kg/day); monitor fluid and electrolyte balance closely; adjust for renal function and comorbidities; rate reduction may be needed due to decreased metabolic reserve.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
None (not FDA-approved, but similar parenteral nutrition products carry warnings for metabolic complications, including hyperglycemia, hyperosmolar coma, and electrolyte imbalances; use in patients with severe renal or hepatic disease may require dose adjustments).
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Risk of hyperglycemia, hyperosmolar hyperglycemic state, and rebound hypoglycemia if infusion is stopped abruptly,Monitor serum electrolytes, blood urea nitrogen (BUN), glucose, and liver function tests regularly,Use with caution in patients with renal insufficiency (may require protein restriction), hepatic failure, or metabolic disorders (e.g., maple syrup urine disease),Potential for infection and thrombophlebitis with central venous access,Do not administer if solution is discolored or contains particulate matter
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Known hypersensitivity to any component,Severe hyperglycemia or hyperosmolar state,Uncontrolled metabolic acidosis,Anuria or severe renal impairment (unless dialyzed),Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic insufficiency with encephalopathy
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
None; parenteral nutrition bypasses the gastrointestinal tract. However, monitor blood glucose if patient is on oral hypoglycemics or insulin.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose may cause fetal hyperinsulinemia and hypoglycemia if maternal glucose levels are high. Use only if clearly needed.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Not excreted into milk in significant amounts; ingredients are normal nutrients. Compatible with breastfeeding. M/P ratio not applicable.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
No standard dose adjustment. Monitor glucose levels closely; insulin requirements may increase due to dextrose load. Adjust infusion rate based on metabolic tolerance.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This is a hypertonic solution (4.25% amino acids + 25% dextrose) used for peripheral parenteral nutrition; monitor for phlebitis due to high osmolality (>1000 m Osm/L); requires central venous access for long-term use; check serum electrolytes, glucose, and renal function daily; avoid abrupt discontinuation to prevent rebound hypoglycemia; contraindicated in patients with severe hyperglycemia, azotemia, or lipid metabolism disorders.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This solution is given through a vein to provide nutrition when you cannot eat normally.,Report any pain, redness, or swelling at the infusion site immediately.,You may need regular blood tests to monitor your blood sugar, kidney function, and electrolytes.,Do not stop the infusion suddenly without medical advice, as this may cause low blood sugar.,Inform your healthcare provider if you have diabetes, kidney disease, or any allergies.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is: Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER is classified as Category C. Travasol 4.25% in Dextrose 25% is a parenteral nutrition solution. No specific teratogenic effects are documented; risks are related to underlying maternal malnutrition. Dextrose m. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.